Dyne Therapeutics Inc.
| NYSE: DYN | Healthcare / Biotechnology / USA |
| 17.33 | -0.5500 | -3.08% | Vol 618.98K | 1Y Perf -26.74% |
| Apr 20th, 2021 16:00 DELAYED |
| BID | 16.19 | ASK | 17.58 | ||
| Open | 17.76 | Previous Close | 17.88 | ||
| Pre-Market | - | After-Market | 17.33 | ||
| - - | - -% |
| Target Price | 34.00 | Analyst Rating | — — 0.00 | |
| Potential % | 96.19 | Finscreener Ranking | ★★ — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★+ 60.24 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★ 60.26 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 891.84M | Earnings Rating | Strong Sell | |
| Price Range Ratio 52W % | 20.36 | Earnings Date | 3rd Jun 2021 |
Today's Price Range 16.9918.08 | 52W Range 13.5032.31 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.99% | ||
| 1 Month | 9.61% | ||
| 3 Months | -18.41% | ||
| 6 Months | 1.40% | ||
| 1 Year | -26.74% | ||
| 3 Years | 35.28% | ||
| 5 Years | 3.28% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -16.16 | |||
ROE last 12 Months | -36.13 | |||
ROA (5Y Avg) | -2.92 | |||
ROA last 12 Months | -32.15 | |||
ROC (5Y Avg) | -1.24 | |||
ROC last 12 Months | -9.19 | |||
Return on invested Capital Q | -8.07 | |||
Return on invested Capital Y | -35.93 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 3.50 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.30 | ||||
| 2.29 | ||||
| - | ||||
| 3.50 | ||||
| -31.20 | ||||
| -0.68 | ||||
| 2.29 | ||||
| 8.14 | ||||
| 469.21M | ||||
| Forward PE | -5.77 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 31.50 | ||||
| 31.80 | ||||
| 0.03 | ||||
| 0.03 | ||||
| -149.10 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 39.40 | ||||
| 1.60 | ||||
| 18.60 | ||||
| -23.60 | ||||
| -14.58 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| 25.32 | ||||
| 36.24 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.38 | -0.64 | -68.42 |
| Q03 2020 | -0.88 | -2.01 | -128.41 |
| Q04 2017 | -0.33 | 0.01 | 103.03 |
| Q03 2017 | 0.60 | -0.51 | -185.00 |
| Q02 2017 | -0.22 | -0.83 | -277.27 |
| Q01 2017 | -0.45 | -0.03 | 93.33 |
| Q04 2016 | -0.62 | -0.70 | -12.90 |
| Q03 2016 | 0.07 | 0.01 | -85.71 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.60 | -33.33 | Negative |
| 6/2021 QR | -0.63 | -18.87 | Negative |
| 12/2021 FY | -2.59 | -14.10 | Negative |
| 12/2022 FY | -3.02 | -6.71 | Negative |
| Next Report Date | 3rd Jun 2021 |
| Estimated EPS Next Report | -0.60 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 618.98K |
| Shares Outstanding | 51.46M |
| Trades Count | 2.28K |
| Dollar Volume | 4.59M |
| Avg. Volume | 418.71K |
| Avg. Weekly Volume | 283.38K |
| Avg. Monthly Volume | 247.55K |
| Avg. Quarterly Volume | 465.71K |
Dyne Therapeutics Inc. (NYSE: DYN) stock closed at 17.33 per share at the end of the most recent trading day (a -3.08% change compared to the prior day closing price) with a volume of 618.98K shares and market capitalization of 891.84M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Dyne Therapeutics Inc. CEO is Joshua T. Brumm.
The one-year performance of Dyne Therapeutics Inc. stock is -26.74%, while year-to-date (YTD) performance is -17.48%. DYN stock has a five-year performance of 3.28%. Its 52-week range is between 13.5 and 32.31, which gives DYN stock a 52-week price range ratio of 20.36%
Dyne Therapeutics Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 2.29, a price-to-sale (PS) ratio of -, a price to cashflow ratio of 3.50, a PEG ratio of 2.32, a ROA of -32.15%, a ROC of -9.19% and a ROE of -36.13%. The company’s profit margin is -14.58%, its EBITDA margin is 18.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Dyne Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.60 for the next earnings report. Dyne Therapeutics Inc.’s next earnings report date is 03rd Jun 2021.
The consensus rating of Wall Street analysts for Dyne Therapeutics Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Dyne Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Dyne Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Dyne Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.15, ATR14 : 1.35, CCI20 : 116.61, Chaikin Money Flow : 0.31, MACD : -0.75, Money Flow Index : 76.10, ROC : 15.13, RSI : 42.26, STOCH (14,3) : 95.73, STOCH RSI : 1.00, UO : 68.87, Williams %R : -4.27), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Dyne Therapeutics Inc. in the last 12-months were:
Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
CEO: Joshua T. Brumm
Telephone: +1 781 786-8230
Address: 830 Winter Street, Waltham 02451, MA, US
Number of employees: 36
